--- title: "Earnings To Watch: Henry Schein (HSIC) Reports Q4 Results Tomorrow" type: "News" locale: "en" url: "https://longbridge.com/en/news/276559061.md" description: "Henry Schein (HSIC) is set to report its Q4 results tomorrow, with analysts expecting a 4.8% year-on-year revenue growth. Last quarter, the company exceeded revenue expectations with $3.34 billion, a 5.2% increase. Despite past misses on revenue estimates, analysts have maintained their forecasts. Peers like Envista and Align Technology have shown strong performance, with Envista up 17.8% post-results. The healthcare equipment sector has faced volatility, with Henry Schein's shares up 2.6% recently, currently priced at $79.58 against an average analyst target of $78.14." datetime: "2026-02-23T03:09:34.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276559061.md) - [en](https://longbridge.com/en/news/276559061.md) - [zh-HK](https://longbridge.com/zh-HK/news/276559061.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/276559061.md) | [繁體中文](https://longbridge.com/zh-HK/news/276559061.md) # Earnings To Watch: Henry Schein (HSIC) Reports Q4 Results Tomorrow Dental and medical products company Henry Schein will be reporting results this Tuesday morning. Here’s what to look for. Henry Schein beat analysts’ revenue expectations last quarter, reporting revenues of $3.34 billion, up 5.2% year on year. It was a strong quarter for the company, with an impressive beat of analysts’ full-year EPS guidance estimates and a decent beat of analysts’ revenue estimates. Is Henry Schein a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members. This quarter, the market is expecting Henry Schein’s revenue to grow 4.8% year on year, in line with the 5.8% increase it recorded in the same quarter last year. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Henry Schein has missed Wall Street’s revenue estimates multiple times over the last two years. Looking at Henry Schein’s peers in the healthcare equipment and supplies segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Envista delivered year-on-year revenue growth of 15%, beating analysts’ expectations by 10.6%, and Align Technology reported revenues up 5.3%, topping estimates by 1.2%. Envista traded up 17.8% following the results while Align Technology was also up 8.9%. Read our full analysis of Envista’s results here and Align Technology’s results here. Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.4% on average over the last month. Henry Schein is up 2.6% during the same time and is heading into earnings with an average analyst price target of $78.14 (compared to the current share price of $79.58). ### Related Stocks - [Envista Holdings Corporation (NVST.US)](https://longbridge.com/en/quote/NVST.US.md) - [Align Technology, Inc. (ALGN.US)](https://longbridge.com/en/quote/ALGN.US.md) - [Henry Schein, Inc. (HSIC.US)](https://longbridge.com/en/quote/HSIC.US.md) - [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md) - [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md) - [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md) ## Related News & Research - [ENDRA Life Sciences Q4 net loss narrows](https://longbridge.com/en/news/281239377.md) - [Canada's Perimeter Medical Imaging prelim Q4 revenue jumps 143%](https://longbridge.com/en/news/281240360.md) - [Analyst Expectations For Henry Schein's Future](https://longbridge.com/en/news/276793827.md) - [Ventripoint Diagnostics Announces Collaboration with the Health Division of the Montecristo Group](https://longbridge.com/en/news/281455909.md) - [AngioDynamics Q3 revenue beats estimates on Med Tech strength, raises outlook](https://longbridge.com/en/news/281504186.md)